On November 15, 2022 AskGene reported that the pre-clinical results of ASKG315 (IL-15 prodrug) and ASKG915 (PD-1/IL-15 prodrug) at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 37th Annual Meeting in Boston on November 8 – 12, 2022. For ASKG315 phase I clinical study design was also presented (Press release, AskGene Pharmaceuticals, NOV 15, 2022, View Source [SID1234624091]). The two posters were:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
#1101, Chunxiao Yu et al., ASKG315 – An IL-15 Prodrug with Antibody-like PK, Enhanced Safety and Expanded Therapeutic Window
#1183, Kurt Shanebeck et al., ASKG915 – An Anti-PD-1 Antibody-IL-15 Prodrug Fusion Molecule with Enhanced Therapeutic Potential
About ASKG315
ASKG315 is the first prodrug molecule derived from the SmartKine platform, which is AskGene’s proprietary cytokine prodrug technology platform. It is projected to be the world’s first IL-15 prodrug to enter clinical development. Preclinical data of ASKG315 showed that this molecule can selectively activate NK cells and CD8+ cells. Compared to previous generations of cytokine drugs, the prodrug design effectively improved the safety window, significantly extended the half-life, and reduced toxicity. ASKG315 has been approved for clinical trials in Australia and China, and phase I trials will be initiated in both countries in the near future.
About ASKG915
ASKG915 is projected to be the world’s first PD-1 antibody-IL-15 prodrug fusion molecule to enter clinical development. The molecule can achieve tumor targeting through PD-1 and be locally activated at the tumor site. At the same time, the molecule can achieve high dosage, so the PD-1 antibody has full PD-1 blockage functionality. Preclinical data showed that ASKG915 has extended PK, significantly better efficacy than PD-1 antibody monotherapy, and expanded therapeutic window. ASKG915 is expected to benefit more patients than existing PD-1 antibody monotherapies. IND applications for ASKG915 will be submitted in US and China in the fourth quarter of 2022. Phase I clinical trials are expected in 2023.